

General description

Imatinib is a BCR-ABL tyrosine kinase inhibitor used in treatment protocols for various leukaemias and solid tumours.

INN	Imatinib
ATC codes	L01EA01
Medicine type	Chemical agent
EML status history	First added in 2015 (TRS 994) for Chronic myeloid leukaemia, not elsewhere classified Added in 2015 (TRS 994) for Gastrointestinal stromal tumour of unspecified gastrointestinal sites Added in 2021 (TRS 1035) for B lymphoblastic leukaemia or lymphoma with t(9;22) (q34;q11.2); BCR-ABL1
Wikipedia	Imatinib 
DrugBank	Imatinib 

Recommendations

Section Targeted therapies

Oral > Solid: 100 mg; 400 mg

Indications

Chronic myeloid leukaemia, not elsewhere classified

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

B lymphoblastic leukaemia or lymphoma with t(9;22) (q34;q11.2); BCR-ABL1

